排序
2023NICE技术鉴定指导意见:曲妥珠单抗deruxtecan用于在1次或多次抗HER2治疗后治疗HER2阳性不可切除或转移性乳腺癌[TA862]
NENatonalinsutute forHealth and Care ExcellenceNICE贝guidanceTrastuzumab deruxtecanfor treating HER2-positiveunresectable or metastaticbreast cancer after 1 ormore anti-HER2treatme...
2023NPF指南:银屑病的远程医疗管理
ORIGINAL ARTICLE★National Psoriasis FoundationTelemedicine Task Force guidance formanagement of psoriatic diseasevia telemedicineNatalia Pelet del Toro,MD,*Rayan Yahia,BS,Steven R...
2023SOGC临床实践指南:引产(No.432c)
SOGC CLINICAL PRACTICE GUIDELINEIt is the Society of Obstetricians and Gynaecologists of Canada(SOGC)policy to review the content 5 years after publication,at whichtime the documen...
2023巴西专家共识建议:复发/转移性子宫内膜癌患者的管理
frontiers Frontiers in OncologyTYPE Original ResearchPUBLISHED 09 March 2023Do110.3389/fomc2023.1133277Check for updatesManagement of patientsOPEN ACCESSwith recurrent/metastaticSa...
2023共识指南:甲氨蝶呤治疗儿童炎症性皮肤病
真Check for updatesReceived:19 December 2022 Accepted:26 March 2023D0:10.1111/pde.15327Pediatric,PEDRA ORIGINALARTICLEDermatologyWILEYMethotrexate for inflammatory skin disease in ...
2023年V1版《美国国立综合癌症网络儿童中枢神经系统肿瘤实践指南》解读
临床外杂表2023年1月第31卷第1期JClin Surg,an2023,Val.3L,Na.11▣.▣[D010.3969/j.in.10056483.2023.01.001hp:/1www.lewkz.eom/CN/10.3969/j.isn.10056483.2023.01.00l·专家笔谈·▣数:Jouma...
2023意大利实践建议:长期COVID患者的管理
frontiersTYPE Policy and Practice ReviewsFrontiers in Public HealthPUBLISHED 20 April 2023Do110.3389/fpubh20231122141Check for updatesItalian good practiceOPEN ACCESSrecommendation...
2023专家共识声明:注意力缺陷/多动障碍和物质使用障碍患者的识别和治疗
World Journal ofPsychiatrySubmit a Manuscript:https://www.f6publishing.comWorl Psydaiatry 2023 March 19;13(3):84-112DO:105498/wjp.v13.3.84ISSN 2220-3206 (online)EXPERTCONSENSUSlden...
Cancer-RelatedFatigue2023.V1EN
National ComprehensiveNCCNCancer NetworkRNCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines)Cancer-Related FatigueVersion 2.2023-January 30,2023NCCN.orgContinue
MelanomaUveal2023.V1EN
National ComprehensiveNCCNCancer NetworkRNCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines)Melanoma:UvealVersion 1.2023-May 4,2023NCCN.orgContinue
![2023NICE技术鉴定指导意见:曲妥珠单抗deruxtecan用于在1次或多次抗HER2治疗后治疗HER2阳性不可切除或转移性乳腺癌[TA862]-医知素材库](https://cdn.jiaoyuwz.com/2023NICE技术鉴定指导意见:曲妥珠单抗deruxtecan用于在1次或多次抗HER2治疗后治疗HER2阳性不可切除或转移性乳腺癌[TA862]-816b7b06b5-pdf-1.webp)

-fa6bc77ce3-pdf-1.webp)







